CAS Number: 1197953-54-0
Brigatinib is a type of cancer drug known as an ALK (anaplastic lymphoma kinase) inhibitor. It works by blocking the activity of ALK, a protein that is often over-expressed in certain types of cancer cells, such as non-small cell lung cancer (NSCLC).
The over-expression of ALK leads to uncontrolled cell growth and division, which is a hallmark of cancer. Brigatinib interferes with the activity of ALK by binding to the ALK protein and preventing it from interacting with other proteins that are essential for cell survival and proliferation.
By inhibiting the activity of ALK, brigatinib can help to slow the growth and spread of cancer cells. This can lead to a reduction in the size of tumors and an improvement in overall cancer symptoms.
It is important to note that the mechanism of action of brigatinib may vary depending on the type and stage of cancer being treated. The use of brigatinib should be guided by the recommendations of a healthcare provider who is familiar with the patient's medical history and current condition.
Brigatinib is a medication that is used to treat a type of cancer known as non-small cell lung cancer (NSCLC). Specifically, it is indicated for the treatment of patients with ALK (anaplastic lymphoma kinase) positive NSCLC who have progressed on or are intolerant to crizotinib.
ALK positive NSCLC is a subtype of NSCLC that is characterized by a genetic alteration in the ALK gene. This alteration leads to the over-expression of ALK, which drives the growth and spread of cancer cells.
Brigatinib works by inhibiting the activity of ALK, which helps to slow the growth and spread of cancer cells. By doing so, it can help to reduce the size of tumors and improve overall cancer symptoms.
It is important to note that the use of brigatinib should be guided by the recommendations of a healthcare provider who is familiar with the patient's medical history and current condition. The drug should only be used in patients with ALK positive NSCLC, as its safety and efficacy have not been established in other types of cancer.
Headquartered in Hyderabad, India, Dr. Reddy's Laboratories is one of the leading Active Pharmaceutical Ingredients (API) manufacturers and suppliers globally for Brigatinib API. Dr. Reddy's API business is a preferred partner to pharma companies across the US, Europe, Brazil, Latin America, Japan, China, Korea, Middle East and other emerging markets.
Dr. Reddy's API business thrives on the deep technical strengths established over the last 30+ years in the development and manufacture of complex APIs such as steroids, peptides, complex long chain molecules and highly potent APIs (HPAPIs / oncology drugs). This expertise is complemented by our prowess in intellectual property and regulatory affairs which helps us consistently meet and exceed regulatory standards. Dr. Reddy's Brigatinib API is the outcome of the extensive expertise in R&D, IP, and Regulatory.
A key component in helping our customers be first to market is a responsive supply chain. We achieve this by making sure that all our facilities are operating efficiently and to the latest standards of quality, safety, and productivity. A strong interconnect between business and factories allows for a quick reaction to dynamic market changes, so that we can avert shortages and meet sudden surges in demand.
Please fill in the following form for API Requirement & we'll get back to you shortly
No information in this catalog - including any reference to any product or service - constitutes an offer for sale, or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, the research quantities of such products may be offered for the purpose of regulatory submissions, wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the patent scenario for their respective markets and will be responsible for all patent related liabilities. Products protected under valid patents in India are not available for commercial use but would be available for Section 107A purposes.